article thumbnail

The Sham Litigation Exception after AbbVie - Is the Subjective Element a Sham?

JD Supra Law

The Federal Trade Commission (“FTC”) sued AbbVie and Besins Healthcare, co-owners of a patent that covered brand AndroGel, in 2017. The FTC claimed that the manufacturers had brought “sham” patent infringement litigation in 2011 against Teva and another generic supplier, Perrigo. Actavis, in violation of Section 5.

article thumbnail

Genentech BPCIA Trastuzumab Case Against Tanvez Dismissed After Settlement

LexBlog IP

As previously reported , Genentech and Tanvex reached an agreement in January 2022 to settle BPCIA litigation relating to Tanvex’s biosimilar of HERCEPTIN (trastuzumab). The post Genentech BPCIA Trastuzumab Case Against Tanvez Dismissed After Settlement appeared first on Big Molecule Watch.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DDE Excludes Damages Testimony Based on “Built-In Apportionment,” Prior Jury Verdicts, and Settlement Agreements

Fish & Richardson Trademark & Copyright Thoughts

Stec, from testifying as to reasonable royalty damages, where Dr. Stec had relied on a license agreement between third parties, jury verdicts, and settlement agreements. Dr. Stec cited a number of agreements, but the only one he relied on that was not a litigation settlement was between iPIN Debit Network, Inc. iPIN license”).

article thumbnail

Medical Device Companies Settle Trade Secrets Dispute for $8,000,000

Trading Secrets

In 2017, Life Spine entered into various agreements with Aegis by which Aegis would sell and distribute ProLift devices while maintaining as confidential all proprietary information related to the devices. Litigation continued for years, with Aegis raising unsuccessful counterclaims.

article thumbnail

Medical Device Companies Settle Trade Secrets Dispute for $8,000,000

LexBlog IP

In 2017, Life Spine entered into various agreements with Aegis by which Aegis would sell and distribute ProLift devices while maintaining as confidential all proprietary information related to the devices. Litigation continued for years, with Aegis raising unsuccessful counterclaims.

article thumbnail

3 Count: Servant Returns

Plagiarism Today

The service disappeared from the internet in June 2017 as the result of a lawsuit and an injunction filed in Canada against Lackman. 3: Nykaa Settles Copyright Infringement Litigation With L’Oreal, Stocks Rally Post News. 3: Nykaa Settles Copyright Infringement Litigation With L’Oreal, Stocks Rally Post News.

article thumbnail

FDA Approves Interchangeable Status for BI’s Adalimumab Biosimilar Cyltezo

LexBlog IP

Although approved in August 2017, CYLTEZO is not scheduled to launch until July 1, 2023, pursuant to a settlement agreement with AbbVie arising from the Humira litigation. BI’s adalimumab biosimilar CYLTEZO (adalimumab-adbm) has recently been granted interchangeable status by the FDA.